|21st October 2020||Joseph S Zakrzewski||100,000||Exercise of derivative||$3.40||$340,000.00|
|9th September 2020||Kenneth J. Hillan||15,000||Grant/award etc.||$0.00|
|24th August 2020||Robert Carey||10,000||Open or private purchase||$5.70||$57,000.00|
|14th August 2020||Robert Carey||10,000||Open or private purchase||$5.50||$55,000.00|
|14th August 2020||Robert Carey||50,000||Open or private purchase||$5.65||$282,500.00|
|13th August 2020||Robert Carey||5,000||Open or private purchase||$5.45||$27,250.00|
|13th August 2020||Robert Carey||5,000||Open or private purchase||$5.30||$26,500.00|
|25th June 2020||David Mark Mc Clung||100,000||Grant/award etc.||$0.00|
|16th June 2020||Stephen George Dilly||17,905||Grant/award etc.||$0.00|
|11th June 2020||Karen L. Smith||30,220||Grant/award etc.||$2.73||$82,500.60|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.
Sangamo Therapeutics, Inc. engages in researching and developing transcription factors in the regulation of genes. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Richmond, CA.